BioSpace News Archive

Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. announced that the company is collaborating with Amazon Web Services, Inc. and Onica, a Rackspace Technology company, to build and host its Digital Health Platform.

Affinivax, Inc. (“Affinivax”), a clinical stage biotechnology company with its novel MAPS™ technology platform for vaccines and immunotherapies, today announced the presentation of initial data from a Phase 1/2 clinical trial of its lead vaccine candidate targeting Streptococcus pneumoniae (ASP3772, partnered with Astellas Pharma Inc.)

Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, announced today that Dania Rabah, Ph.D., has been hired as the company’s Chief Scientific Officer.

Now In Its 14th Year, Practice Pink Has Raised More Than $1.7M for Cancer Research, Prevention, and Awareness Efforts

Exergen Corporation Launches Nurse Support Program to Ensure Every Nurse Has Access to an Accurate Thermometer at Home to Protect Themselves and Their Families

VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator in vessel preparation for interventional treatment of peripheral arterial disease (PAD) and stenoses of arteriovenous (AV) fistulas and grafts, announced today that the U.S. Food and Drug Administration (FDA) cleared the Company’s FLEX Vessel Prep™ System for use in the treatment of in-stent restenosis (ISR) in the peripheral vasculature.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-stage, novel broad-spectrum antifungal, ibrexafungerp, at IDWeek 2020.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced today that data from its NUZYRA (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2020 virtual meeting. NUZYRA is a once-daily oral and

Findings Show Less Than 1% Device Related Complications Nearly 1.3 Million Implants Placed Worldwide SANTA BARBARA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, is today announcing its latest clinical data demonstrating 10 years of outstanding safety outcomes reported in women who have received the Company’s Motiva ® silico

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office. The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment o